- Secured material 라이브바카라 for inclusion of ‘sialic acid’ as a component on protein surface
- Structural patent re라이브바카라stration imminent… Enables response to avoid biosimilar evasion attempts
[by Sung, Jae Jun] GI Innovation announced on June 12 that a material patent based on the sialic acid content of its next-generation allergy treatment candidate, 'GI-301 (or development code: YH35324),' has been officially registered in the United States.
This patent defines 라이브바카라301 as a protein containing a specified percentage of sialic acid, a sugar component present on the protein surface. Sialic acid serves as a quality indicator influencing the half-life, stability, and suitability for repeated administration of protein-based drugs. The patent is regarded as a protective measure that encompasses the quality attributes of 라이브바카라301.
The company stated that a structural patent based on the amino acid sequence of 라이브바카라301 is also nearing registration. GI Innovation anticipates that securing both patents will substantially enhance the intellectual property protection of 라이브바카라301, covering its structural composition and quality attributes.
In particular, the sialic acid-based 라이브바카라 is expected to serve as a defensive mechanism against attempts to develop biosimilars and biobetters through modifications to amino acid sequences or variations in manufacturing processes.
"This patent means that 라이브바카라301 has been acknowledged for its competitiveness not only in structural aspects but also in terms of quality," said Jang Myoung-ho, CEO of GI Innovation. "It lays the foundation for positioning the drug as a competitive subcutaneous injection therapy in the global market."
라이브바카라301 is a protein-based novel drug candidate for which GI Innovation licensed out technology to Yuhan Corporation in 2020 in a deal valued at around KRW 1.4 trillion (approximately USD 1 billion). The candidate has completed Phase 1 clinical trials and is currently preparing to enter phase 2 clinical studies.
Yuhan Corporation plans to present clinical results for GI-301, targeting patients unresponsive to 'Xolair,' at the European Association of Allergy & Immunology (EAACI) conference scheduled for June 13.